Protalix BioTherapeutics (PLX) Gross Profit Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.21% |
| Dec 31, 2025 | -23.10% |
| Sep 30, 2025 | 3.76% |
| Jun 30, 2025 | 1.38% |
| Mar 31, 2025 | -36.15% |
| Dec 31, 2024 | 5.38% |
| Sep 30, 2024 | -2.79% |
| Jun 30, 2024 | -15.90% |
| Mar 31, 2024 | -32.85% |
| Dec 31, 2023 | 38.64% |
| Sep 30, 2023 | 44.72% |
| Jun 30, 2023 | 177.79% |
| Mar 31, 2023 | 31.90% |
| Dec 31, 2022 | 46.71% |
| Sep 30, 2022 | 37.24% |
| Jun 30, 2022 | 41.08% |
| Mar 31, 2022 | 65.85% |
| Dec 31, 2021 | 111.05% |
| Sep 30, 2021 | 81.67% |
| Jun 30, 2021 | 78.30% |
| Mar 31, 2021 | 111.20% |
| Sep 30, 2020 | 48.07% |
| Jun 30, 2020 | 52.42% |
| Mar 31, 2020 | 66.83% |
| Mar 31, 2019 | 20.46% |
| Dec 31, 2018 | 39.64% |
| Sep 30, 2018 | -22.04% |
| Jun 30, 2018 | -16.01% |
| Mar 31, 2018 | -11.48% |
| Dec 31, 2017 | 22.95% |
| Sep 30, 2017 | -13.55% |
| Jun 30, 2017 | -48.01% |
| Mar 31, 2017 | -19.76% |
| Dec 31, 2016 | -15.19% |
| Sep 30, 2016 | -9.02% |
| Jun 30, 2016 | 15.10% |
| Mar 31, 2016 | -50.45% |
| Sep 30, 2015 | -12.08% |
| Jun 30, 2015 | 12.63% |